Taxol, rii y extrced fro the bark of the western yew, Taxus brenfolia, is reportedly the first of a new class of anti-cancer agent. It Taxol, reportedly the first of a new class of anti-cancer agents, was originally extracted from the bark of the western yew, Taxus brevifolia (1). In vivo, it prevents the disassembly of microtubules, causing the arrest of cells at the G2/M step of the cell cycle (2). Its mechanism differs from that of other anti-cancer agents that have tubulin as their target, such as colchicine, podophyllotoxin, or vinblastine, which inhibit tubulin polymerization (3). The site of action of taxol on tubulin is being investigated in several laboratories. Photoaffinity-labeling experiments implicate the N-terminal region of (3-tubulin as the site of attachment (4, 5).
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With the aim of using immunological techniques to investigate the action of taxol, we sought to prepare an anti-idiotypic antibody that mimics taxol, using an auto-anti-idiotypic strategy (6, 7). We (8) .
Preparation of Fab fragments of R585. Rabbit anti-taxol antiserum R585 (8) was affinity-purified as follows. Two affinity columns were prepared. Either 10 mg of bovine serum albumin (BSA) or 10 mg of taxol covalently linked to rabbit serum albumin (taxol-RSA) (8) was dissolved in 1 ml of 0.1 M 2-(N-morpholino)-ethanesulfonic acid (Mes) buffer (pH 4.8) and added to 2 ml of Affi-Gel 10 (Bio-Rad). The mixtures were rocked gently overnight at 40C. The gels were then washed with several column volumes of phosphatebuffered saline (PBS, pH 7.3) and with 0.2 M glycine hydrochloride buffer (pH 2.5) and then equilibrated with PBS. Six milliliters of R585 antiserum was first recirculated through the taxol-RSA-Affi-Gel 10 column overnight at 40C at a rate of0.2 ml/min. The column was then extensively washed with PBS at a rate of 1.0 ml/min to remove all nonspecifically bound proteins. The antibodies were then eluted with 0.2 M glycine hydrochloride (pH 2.5) at a rate of 0.5 ml/min. The eluted antibodies were immediately neutralized with 2 M Tris base and dialyzed against PBS at 40C overnight. On the following day, the eluted antibodies were recycled through the BSA-Affi-Gel 10 column at 40C overnight to remove BSA-binding antibodies. The effluent, which contained antitaxol antibodies in PBS, was collected and concentrated by a Centriprep-10 concentrator (Amicon) to a volume of 1-2 ml.
Fab fragments were prepared from the affinity-purified antibodies as described (9) .
Screening for anti-idiotypic antibodies. A competitive ELISA was used to assay for taxol-inhibitable binding to the Fab fiagments of affinity-purified R585. The ELISA was run as described for the characterization of anti-taxol antibodies (8) (10) . Fab fragments were prepared from affinitypurified 82H by a previously described procedure (11) . Microtubules were prepared from fresh calf brain according to the procedure of Shelanski et al. (12) . The inhibition assay was according to Parness et al. (13) with minor modifications to accommodate the antibody. Tubulin was freshly prepared from a microtubule pellet by suspending it in Mes buffer (0.1 M Mes/0.5 mM MgC12/1 mM EGTA, pH 6.6) plus 3 mM GTP for 30 min at 40C to induce depolymerization. This was followed by centrifugation at 100,000 x g for 20 min at 40C.
The clarified supernatant was assayed for protein content by the Bradford procedure (14) and used in the assay.
The tubulin solution (400 pA, 1.5 mg/ml) was incubated at 37TC for 40 mim in Mes buffer/3 mM GTP to regenerate the Abbreviations: V, variable; J, joining; CDR, complementaritydetermining region; BSA, bovine serum albumin.
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microtubules. (19) .
The plasmids of the colonies with correct inserts were purified for sequencing using a plasmid preparation kit (Qiagen, Chatsworth, CA) according to the manufacturer's protocol. Sequencing was performed by the dideoxynucleotide chain-termination method with a Sequenase kit (United States Biochemical, Version 2.0). Several independent clones were sequenced in both directions to get the complete sequence of the V region. CAG ATC CAG TTG GTG CAG TCT GGA CCT GAG CTG AAG AAG CCT GGA GAG ACA GTC AAG ATC 60 TOC TGC AAG GCT TCT GGT TAT GCC TTC ACA GAC TAT TCA ATG CAC TGG GTG AAG CAG GCT omas were prepared as described for the isolation of monoclonal anti-taxol antibodies (8) (20) , both active anti-tumor agents, but not by baccatin III, a structurally related compound devoid of anti-tumor activity (Fig. 1) .
RESULTS

Isolation
(ii) Antibody 82H and its Fab fragment inhibited the binding of [3H]taxol to microtubules with an IC50 of 1 PM and 3 uM, respectively (Fig. 2) . A control monoclonal IgG2b antibody, 26F, specific for thymine glycol (21), was inactive. The reliability of the assay was tested by assaying for inhibition by taxol, taxotere, and baccatin III. Taxol and taxotere inhibited binding: IC50 3 pM for both; no inhibition was seen with baccatin III (data not shown). Control experiments were also run to show that 82H did not bind taxol.
(iii) When incubated with tubulin at 37°C, and the assembling of microtubules was followed turbidimetrically (13), 82H and its Fab fragment induced the formation of microtubules, which, like those produced by taxol, were not dissociated by Ca2+ (22) . As with taxol, the curves were sigmoidal, although the lag periods for the antibody and its Fab were considerably longer, that of the intact antibody being the longest (Fig. 3) . This is in accord with the relatively high molecular weights of the immunoglobulin molecules compared to taxol, which would result in a slower rate of diffusion (ref. 23, pp. 582-584) . Added to that is the lesser probability of a productive collision than in the case of taxol-i.e., one in which contact is made by the combining site of the antibody, which occupies a relatively small site in the immunoglobulins.
Electron Microscopic Examination of the Putative Microtubules. Electron microscopic examination of the product induced by intact antibody revealed typical microtubule structures (24) with arrays of antibody-like molecules along the surface (Fig. 4) (26) .
The amino acid sequence of the heavy chain of 82H (Fig.  5) , up to the CDR3 region, was almost identical to that of an anti-idiotypic antibody to an anti-insulin antibody, except for three amino acids in framework regions at positions 10, 28, and 39 (27) . Its CDR3 sequence, however, was markedly different: VFYDGYYAWFPY vs. EYAPYFDV in 82H.
DISCUSSION
The concept of the "internal image" was put forth by Jerne (28, 29) and expanded upon by others (30) (31) (32) . This concept implies that the immune repertoire is diverse enough to contain immunoglobulins with specificities that "reflect the outside world" (29). It would follow, then, that with appropriate rigorous screening and detection procedures antibodies could be found that mimicked "any" antigen in the outside world.
This idea is by no means universally accepted. For example, a recent article claimed to have "undermined" the concept of mimicry between antibodies, receptors, and their ligands (33) . The criticism was applied particularly to mimicry by antibodies that bear no structural similarity to the immunizing ligand, which was described as a "chance event of incalculable frequency" (34) .
Antibody 82H fits that description-i.e., it bears no structural similarity to taxol. The fact that 82H is anti-idiotypic and was generated and selected deliberately for taxol mimicry should, finally, mute the controversy over the concept of functional mimicry between antibodies, receptors, and their ligands, regardless of perceptions of similarities on the basis of chemical structure. An analogy can be made with the fact that polycyclic opioids and polypeptide endorphins act at the same receptor.
Antibody 82H, rather than just mimicking the binding of taxol to microtubules, is capable of assembling the supramolecular structure from soluble cellular components-i.e., from tubulin. There is no precedent for this kind of activity on the part of an immunoglobulin. It opens up new possibilities for the application of internal image antibodies to the study of biological systems.
We have sequenced the V regions of 82H. The purpose was to gain insight into the peptide sequence(s) responsible for the mimicry, information that can be of value for the design of new anti-cancer agents with taxol-like activity. Because of the apparent importance of the CDR3 sequence for the Proc. Natl. Acad. Sci. USA 91 (1994) specificity of 82H (see above), appropriate peptides can be synthesized to test this possibility. X-ray crystallographic analysis of the structure of the Fab fragment should provide information concerning the conformation of the peptides engaged in the taxol mimicry.
The finding that a polypeptide can mimic taxol raises the possibility that taxol acts as a peptidomimetic compound that interferes with the function of an endogenous cellular polypeptide.
